BTG Pharmaceuticals results - up 7%

BTG reported results on November 12th, 2013 for the six months ending September 30th. Underlying revenues rose 17% to 153 mil. GBP, however after adjusting for non-recurring revenue last year, the growth was close to 28%. It is also the first reporting period that included the acquired products EKOS and TheraSphere in July 2013, which generated revenues of 13.3 million GBP. The company raised guidance for it's flagship drug Varisolve, which is expected to generate more than 500 million USD (close to 300 mil. GPB) revenue in the future. The company is awaiting approval on 4th of December, after which it could start selling it in the first half of 2014. The drug approval is expected by markets, however their revenue could easily double in the next few years, and I think Mr. Market is not realizing the full potential of this company. I keep holding it, as it's still one of the best stocks to buy right now and their results have just proven my bullish analysis. Financials and Fundamentals